Abstract:The Hedgehog (HH) signaling pathway represents an important class of emerging developmental signaling pathways that play critical roles in the genesis of a large number of human cancers. The pharmaceutical industry is currently focused on developing small molecules targeting Smoothened (Smo), a key signaling effector of the HH pathway that regulates the levels and activity of the Gli family of transcription factors. Although one of these compounds, vismodegib, is now FDA-approved for patients with advanced basal cell carcinoma, acquired mutations in Smo can result in rapid relapse. Furthermore, many cancers also exhibit a Smo-independent activation of Gli proteins, an observation that may underlie the limited efficacy of Smo inhibitors in clinical trials against other types of cancer. Thus, there remains a critical need for HH inhibitors with different mechanisms of action, particularly those that act downstream of Smo. Recently, we identified the FDA-approved anti-pinworm compound pyrvinium as a novel, potent (IC50, 10 nmol/L) casein kinase-1α (CK1α) agonist. We show here that pyrvinium is a potent inhibitor of HH signaling, which acts by reducing the stability of the Gli family of transcription factors. Consistent with CK1α agonists acting on these most distal components of the HH signaling pathway, pyrvinium is able to inhibit the activity of a clinically relevant, vismodegib -resistant Smo mutant, as well as the Gli activity resulting from loss of the negative regulator suppressor of fused. We go on to demonstrate the utility of this small molecule in vivo, against the HH-dependent cancer medulloblastoma, attenuating its growth and reducing the expression of HH biomarkers.

A small-molecule antagonist of the hedgehog signaling pathway.

A small molecule that binds Hedgehog and blocks its signaling in human cells

L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in Vitro and in Vivo

Identification of small molecule antagonists of sonic hedgehog/heparin binding with activity in hedgehog functional assays

Discovery and evaluation of potential sonic hedgehog signaling pathway inhibitors using pharmacophore modeling and molecular dynamics simulations

Discovery of Small Molecule Inhibitors Targeting the Sonic Hedgehog

MEKK2 and MEKK3 Suppress Hedgehog Pathway-Dependent Medulloblastoma by Inhibiting GLI1 Function

Small-molecule modulators of the Sonic Hedgehog signaling pathway

Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.

Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.

Syntheses of aminoalcohol-derived macrocycles leading to a small-molecule binder to and inhibitor of Sonic Hedgehog

Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog pathway inhibitor-1

Design, Synthesis, and Evaluation of Inhibitors of Hedgehog Acyltransferase

Synthesis and Evaluation of Novel Benzylphthalazine Derivatives As Hedgehog Signaling Pathway Inhibitors.

ABT-737 Suppresses Aberrant Hedgehog Pathway and Overcomes Resistance to Smoothened Antagonists by Blocking Gli

Casein Kinase 2 Promotes Hedgehog Signaling by Regulating Both Smoothened and Cubitus Interruptus

A PKA inhibitor motif within SMOOTHENED controls Hedgehog signal transduction

Hedgehog Signalling Activity of Smoothened Requires Phosphorylation by Protein Kinase A and Casein Kinase I

Nanomolar, Noncovalent Antagonism of Hedgehog Cholesterolysis: Exception to the “Irreversibility Rule” for Protein Autoprocessing Inhibition

Pyrvinium attenuates Hedgehog signaling downstream of smoothened

Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies